
BIA Separations
A worldwide provider of solutions for biopharmaceutical companies.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
$360m | Acquisition | ||
Total Funding | 000k |
EUR | 2015 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | 93 % | 84 % | 158 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (3 %) | 32 % | 50 % | 60 % | 64 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (328 %) | 19 % | 18 % | 47 % | 50 % |
EV | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | - | - | - | 89 % | - |
Source: Company filings or news article
Related Content
BIA Separations specializes in the development and manufacturing of Convective Interaction Media (CIM) monolithic chromatographic columns, which are essential for the production, purification, and analytics of large biomolecules. The company serves clients in the biopharmaceutical industry, including those involved in gene therapy, vaccine production, and mRNA technologies. Operating in the biotechnology market, BIA Separations employs a business model that focuses on selling high-performance chromatography tools and providing technical support and process development services. Revenue is generated through the direct sale of their proprietary monolithic columns and associated services. The company has been integrated into Sartorius, enhancing its portfolio in gene therapy and vaccine solutions.
Keywords: monolithic columns, chromatography, biopharmaceuticals, gene therapy, vaccine production, mRNA technologies, biomolecule purification, biotechnology, process development, technical support.